Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative
WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...
Recorded Q2'25 consolidated revenue of KRW 1,289.9 billionRecorded Q2'25 consolidated operating profit of KRW 475.6 billionSolid momentum sustained through capacity ramp-up and stable project...
130 Breast Cancer Patients and Survivors Served During Five-Day Distribution of Donated Essentials
TALLAHASSEE, Fla., July 22, 2025 /PRNewswire/ -- United Breast Cancer Foundation (UBCF)...
Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...
In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...
In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...
Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery
SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical...
New initiative enhances the checkpoint experience for families traveling this summer
WASHINGTON, July 18, 2025 /PRNewswire/ -- US Department of Homeland Security Secretary Noem announced...